1156-19-0 | Tolazamide

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$7.00	$5.00
10mg	98%	in stock	$18.00	$13.00
50mg	98%	in stock	$37.00	$26.00
100mg	98%	in stock	$55.00	$38.00
250mg	98%	in stock	$82.00	$57.00
1g	98%	in stock	$203.00	$142.00
5g	98%	in stock	$667.00	$467.00

Description

• Catalog Number: AA20857
• Chemical Name: Tolazamide
• CAS Number: 1156-19-0
• Molecular Formula: C14H21N3O3S
• Molecular Weight: 311.3998
• MDL Number: MFCD00083504
• SMILES: O=C(NS(=O)(=O)c1ccc(cc1)C)NN1CCCCCC1

Computed Properties

• Complexity: 431
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 21
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 3
• XLogP3: 1.5

Literature

• Epac2: a sulfonylurea receptor?

  Biochemical Society transactions 20120201

• The management of type 2 diabetic patients with hypoglycaemic agents.

  ISRN endocrinology 20120101

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor γ Activity and on Glucose Uptake by Thiazolidinediones.

  Diabetes & metabolism journal 20110801

• Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study.

  Diabetes care 20110601

• Primary language, income and the intensification of anti-glycemic medications in managed care: the (TRIAD) study.

  Journal of general internal medicine 20110501

• A predictive ligand-based Bayesian model for human drug-induced liver injury.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• Glucose biosensors: an overview of use in clinical practice.

  Sensors (Basel, Switzerland) 20100101

• Accuracy of Veterans Affairs databases for diagnoses of chronic diseases.

  Preventing chronic disease 20091001

• The second-meal phenomenon in type 2 diabetes.

  Diabetes care 20090701

• A review of exenatide as adjunctive therapy in patients with type 2 diabetes.

  Drug design, development and therapy 20090101

• Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles.

  PloS one 20090101

• Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

  BMJ (Clinical research ed.) 20090101

• Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.

  Journal of medicinal chemistry 20081113

• Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis.

  Diabetes care 20081101

• Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.

  Nature chemical biology 20080501

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach.

  Journal of medicinal chemistry 20050407

• Effects of sulfonylureas, alpha-endosulfine counterparts, on glomerulosclerosis in type 1 and type 2 models of diabetes.

  Kidney international 20050201

• Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20050101

• Detection of anti-diabetics in equine plasma and urine by liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041105

• Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus.

  The Annals of pharmacotherapy 20031101

• Selection of drugs to test the specificity of the Tg.AC assay by screening for induction of the gadd153 promoter in vitro.

  Toxicological sciences : an official journal of the Society of Toxicology 20030801

• Barriers to self-monitoring of blood glucose among adults with diabetes in an HMO: a cross sectional study.

  BMC health services research 20030101

• [A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus].

  Yakushigaku zasshi 20030101

• Screening, library-assisted identification and validated quantification of oral antidiabetics of the sulfonylurea-type in plasma by atmospheric pressure chemical ionization liquid chromatography-mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020615

• Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

  The Journal of biological chemistry 20020419

• The structure and function of the ATP-sensitive K+ channel in insulin-secreting pancreatic beta-cells.

  Journal of molecular endocrinology 19990401

• Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor.

  Science (New York, N.Y.) 19951117

• Oral hypoglycemic agents in the treatment of type II diabetes.

  American family physician 19931101

• Transketolase abnormality in tolazamide-induced Wernicke's encephalopathy.

  Neurology 19861101

• A case of chronic liver disease due to tolazamide.

  Gastroenterology 19850701

• Wernicke's encephalopathy induced by tolazamide.

  The New England journal of medicine 19830908

• The effect of chlorpropamide hyponatremia on mental status in a nursing home population.

  The Journal of family practice 19830501

• Potentiation of insulin action by a sulfonylurea in primary cultures of hepatocytes from normal and diabetic rats.

  Diabetes 19830301

• Tolazamide-induced cholestasis.

  Southern medical journal 19800801

• Reduction of the severity of nephropathy in aging Fischer 344 rats treated with analogs of arylsulfonyluria.

  Toxicology and applied pharmacology 19790701